Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal?
Biohaven (BHVN) announced a global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, including opakalim for focal epilepsy. The stock has seen significant gains, with a 90-day return of 52.12% and a year-to-date return of 42.16%. However, it trades at a high price-to-book ratio of 190.4x, raising valuation concerns. Analysts expect Biohaven to remain unprofitable over the next 3 years, with no meaningful revenue and a net loss of $586.841m.
How this was made
The 30-second read
Why it matters
The licensing agreement provides a potential new revenue stream but does not address the company's large net loss.
Market read
Primary relevance to Biohaven (BHVN); peers may be indirectly affected by sector sentiment.
What to watch
Absence of disclosed upfront payment or milestone structure leaves upside uncertain.
Background
Biohaven's share price has surged 52% over 90 days, driven by optimism around its pipeline.
Ticker impact
Biohaven announced a global licensing and collaboration agreement granting SK Biopharma exclusive rights to its Kv7 ion channel platform.
Modest upside potential if partnership milestones are met; downside risk if trials disappoint.
No financial terms disclosed, so market reaction will depend on future trial data and milestone payments.
Market effects
Highlights continued interest in ion‑channel therapeutics within biotech.
May increase visibility of SK Biopharma in the Asian market.
Limited; primarily affects Biohaven and its peers.
Counterpoint
The licensing deal may be overhyped; Biohaven remains vastly overvalued on fundamentals.
Key entities
- CompanyBiohaven Pharmaceutical
US‑listed biotech developing Kv7 ion channel therapies.
- CompanySK Biopharma
South Korean partner receiving exclusive rights.
